Business
ABEO: Sells Priority Review Voucher for $155 Million…
By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update First Qualified Treatment Center Activated On May 14, 2025, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the Ann & Robert H. Lurie Children’s Hospital of Chicago has been activated as the first Qualified Treatment Center (QTC) for Zevaskyn™. The hospital has completed all QTC start-up activities and
About this update from Abeona Therapeutics Inc.
[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:ABEO","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL ABEO RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"First Qualified Treatment Center Activated","length":42,"tagName":"p"},{"type":"text","content":"On May 14, 2025, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the Ann & Robert H. Lurie Children’s Hospital of Chicago has been activated as the first Qualified Treatment Center (QTC) for Zevaskyn™. The hospital has completed all QTC start-up activities and the first patient is likely to be biopsied in July and treated in August.","length":345,"tagName":"p"},{"type":"text","content":"Lurie Children’s is one of the largest North American centers for epidermolysis bullosa and cares for more than 150 affected children and adults. Zevaskyn will be the tenth gene therapy offered at Lurie Children’s.","length":214,"tagName":"p"},{"type":"text","content":"Commercial Launch Underway","length":26,"tagName":"p"},{"type":"text","content":"Following the approval of Zevaskyn on April 29, 2025, Abeona is focused on advancing its commercial launch and identifying patients eligible for treatment. The company reported that since the drug was approved, approximately 30 patients and caregivers have started registering in the Abeona Assist patient services program. Management has guided that between 10-14 patients are expected to be treated, and revenue recognized from those treatments, this year. Manufacturing capacity is expected to be able to handle up to six treatments per month by the end of 2025 and up to 10 treatments per month by mid-2026.","length":611,"tagName":"p"},{"type":"text","content":"PRV Sale Strengthens Balance Sheet","length":34,"tagName":"p"},{"type":"text","content":"On May 12, 2025, Abeona announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million (our estimate was for $150 million). The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvement Act. With the proceeds from the sale, the company now has sufficie...